How Does This Biotech Generate Its Revenue?
Regeneron Pharmaceuticals is a biotechnology company that develops and commercializes medicines. The business is built around bringing therapies to market and generating revenue from those products. It operates at large scale, with a market capitalization around USD 78.9 billion. The company’s results tend to be driven by how consistently its portfolio converts sales into profit and cash.
Are Strong Margins Offsetting Slower Growth?
FundamentalsFor 2025, reported in USD, revenue reached about USD 14.3 billion, alongside EBIT of roughly USD 3.6 billion and net income of about USD 4.5 billion. Revenue growth was 1.0% year over year, while margins remained elevated, including an 86.56% gross margin and a 24.95% operating margin.
Cash conversion, based on the provided proxy, was around USD 2.5 billion, with depreciation and amortization at roughly USD 544 million and capital spending at about USD 898 million. The balance sheet held about USD 3.1 billion of cash against USD 2.0 billion of total debt.
Is The Market Pricing Steady Profitability Fairly?
DCF / MultiplesAt USD 746, the current price sits above the weaker end of the DCF outcomes but below the central and stronger outcomes. The headline multiples at this price include a 17.69 P/E and 15.29 EV/EBITDA, framing the stock as priced for ongoing earnings power rather than a reset lower.
Execution Remains The Key Factor
TakeawayThe operating model is built on exceptional gross profitability. Durability depends on keeping operating costs controlled as revenue growth stays low. Cash generation needs to remain steady after capital spending. If margins fade, the earnings base can shrink quickly. If execution holds, the business can compound through consistency.